Objective: To evaluate the value of the age-adjusted Charlson comorbidity Index (ACCI) in predicting the prognosis and guiding the clinical treatment of laryngeal squamous cell carcinoma (LSCC) in patients over 60 years old. Methods: Retrospective analysis of 249 cases of LSCC in Shanxi Provincial Cancer Hospital and First Hospital of Shanxi Medical University from 2008 to 2015 was performed. There were 234 males and 15 females, aged from 60 to 88 years. The clinical characteristics, treatment information and follow-up data were collected. ACCI was used to score the comorbidities of the patients. Receiver operating characteristic (ROC) curve was drawn and the patients were divided into high ACCI group and low ACCI group according to the cut-off value of ACCI. Prognostic factors were analyzed. Kaplan-Meier method was used for survival analysis, rank sum test was used for comparison between groups, χ2 test was used for enumeration data. Results: Overall survival (OS) was 54.6%, progression-free survival (PFS) was 59.4%, and cancer-specific survival (CSS) was 58.6%. Both the median survival time and PFS time were 60 months. The best cutoff point of the ACCI group was 5. Cox multivariate analysis showed that ACCI was an independent risk factor for OS, PFS and CSS (OR=1.553, 1.499 and 1.534,respectively, all P<0.05). In the high ACCI group, OS (χ2=4.120 and 4.115,P<0.05) and CSS (χ2=4.510 and 5.009,P<0.05) of patients treated with surgery plus radiotherapy and patients with radiotherapy alone were better than those of patients with surgery alone (P<0.05). But in the low ACCI group, there was no significant difference in prognosis among the three treatment regimens (P>0.05). Conclusion: High ACCI offors important prognostic information for LSCC in patients over 60 years old, and can guide clinical treatment options.
目的： 探讨年龄校正Charlson合并症指数（age-adjusted Charlson comorbidity index，ACCI）在60岁及以上喉鳞状细胞癌（简称鳞癌）患者的预后及临床治疗指导价值。 方法： 回顾性分析2008—2015年山西省肿瘤医院和山西医科大学第一医院收治的符合入组标准的249例≥60岁喉鳞癌患者的病例资料，其中男234例，女15例，年龄60~88岁。收集患者临床特征、治疗信息以及随访数据，并采用ACCI对患者的合并症进行评分。绘制受试者工作特征曲线（receiver operator characteristic curve，简称ROC曲线），根据ACCI的临界值划分ACCI分组为高ACCI组和低ACCI组，同时进行预后相关因素分析。生存分析采用Kaplan-Meier法，组间比较采用秩和检验，计数资料采用χ2 检验，多因素分析采用多因素Cox比例风险回归模型分析。 结果： 249例喉鳞癌患者的5年生存率为54.6%，5年无进展生存（progression-free survival，PFS）率为59.4%，癌症特异性生存（cancer‐specific survival，CSS）率为58.6%，中位生存期与PFS均为60个月，根据ROC曲线确定ACCI最佳临界点为5，Cox多因素分析发现ACCI是总生存期（overall survival，OS）、PFS、CSS的独立危险因素（OR=1.553、1.499、1.534，P值均<0.05）。高ACCI组中手术+放疗、单纯放疗的OS（χ2=4.120、4.115，P<0.05）、CSS（χ2=4.510、5.009，P<0.05）优于单纯手术，低ACCI组3种治疗方案预后差异无统计学意义（P值均>0.05）。 结论： 高ACCI是60岁以上喉鳞癌患者重要预后信息，并可指导临床治疗方案选择。.